Incyte Corporation — Q1 2012 Form 10-Q
Reporting period: Three months ended March 31, 2012. Incyte is a biopharmaceutical company focused on oncology and inflammation. JAKAFI (ruxolitinib), approved in the U.S. in November 2011 for intermediate- or high-risk myelofibrosis, was its first commercial product.
Financial performance
Amounts below are in millions of dollars, except per-share data.
| Metric | Q1 2012 | Q1 2011 | Change |
|---|---|---|---|
| Total revenue | $36.2 | $32.0 | Up 13% |
| Product revenue, net | $19.3 | $0 | JAKAFI sales began after approval |
| Contract revenue | $16.7 | $31.8 | Down; prior period included a $15.0 Novartis milestone |
| Research and development | $49.0 | $36.3 | Up 35% |
| Selling, general and administrative | $21.4 | $10.8 | Nearly doubled |
| Operating loss | $(34.2) | $(15.8) | Loss widened |
| Net loss | $(45.4) | $(26.5) | Loss widened |
| Net loss per share, basic and diluted | $(0.36) | $(0.21) | |
| Operating cash used | $(54.4) | $(44.2) | Cash use increased |
Product revenue reflected $21.2 million of gross JAKAFI sales to patients, less approximately $1.9 million of estimated rebates, discounts, fees and assistance. Cost of product revenue was negligible at $0.011 million; Incyte cautioned that pre-approval manufacturing costs had been expensed in R&D, so current product costs reflect a lower average unit cost. No meaningful product gross-margin comparison is available.
Financial position and liquidity
- At March 31, cash and cash equivalents were $231.9 million and marketable securities were $4.6 million. Management reported $236.4 million of available cash, cash equivalents and marketable securities, excluding $19.0 million in a funded escrow for senior-note interest payments through October 2012.
- Cash and cash equivalents fell $41.3 million from year-end 2011. Operating activities used $54.4 million; financing activities provided $13.4 million, mainly from stock-plan issuances.
- Total assets were $293.6 million, down from $329.0 million at December 31, 2011. Stockholders’ deficit increased to $248.9 million from $227.1 million.
- Debt principal totaled $420.0 million: $400.0 million of 4.75% convertible senior notes due October 2015 and $20.0 million of Pfizer convertible subordinated notes, due $10.0 million in each of 2013 and 2014. Balance-sheet carrying value of convertible notes was $322.2 million. Senior-note annual interest payments are $19.0 million, assuming no conversion, repurchase or exchange.
- Current liabilities were $142.3 million versus current assets of $276.2 million. The company reported no off-balance-sheet arrangements other than the commitments discussed in the filing.
Material changes and business developments
- JAKAFI commercialization drove new product revenue, while JAKAFI launch-related sales, marketing and staffing contributed to the increase in SG&A. Higher development headcount, clinical-trial activity and laboratory costs increased R&D.
- Contract revenue declined principally because Q1 2011 included a $15.0 million Novartis development milestone. Recurring contract revenue included straight-line recognition of Novartis and Lilly upfront fees.
- One customer represented 37% of Q1 2012 total revenue, compared with 89% in Q1 2011. Three customers accounted for 64% of accounts receivable at quarter-end.
- In April 2012, the European Medicines Agency’s committee recommended approval of ruxolitinib. Incyte expected a $40.0 million Novartis milestone payment in the quarter ending June 30, 2012; this was a subsequent event, not Q1 revenue or cash received.
- Pipeline programs included ruxolitinib Phase III development in polycythemia vera; LY3009104 in Phase IIb trials for rheumatoid arthritis and psoriasis; and early-stage c-MET and IDO programs. Lilly co-development in rheumatoid arthritis requires Incyte to fund 30% of associated development costs from Phase IIb through regulatory approval.
Outlook, commentary and principal risks
- Management said available cash, cash equivalents and marketable securities should cover capital needs for at least the next 12 months. It also warned that losses may continue and profitability may never be achieved; no specific revenue, earnings or cash-flow guidance was provided.
- Incyte used a sell-through method for JAKAFI revenue because it lacked sufficient return history to estimate returns at specialty pharmacies. It planned to move to sell-in recognition once it had sufficient experience to estimate returns. Rebate, chargeback and assistance estimates may require later adjustment.
- Key risks include the uncertain commercial uptake, reimbursement and pricing of JAKAFI; reliance on a limited specialty-pharmacy network and third-party manufacturers; single-source supply exposure; clinical, regulatory and safety uncertainty; and dependence on collaborators whose agreements may be terminated for convenience.
- Substantial leverage and debt covenants may constrain financing and operations. Incyte said future funding needs may require equity, debt or collaborations, which may be unavailable on acceptable terms or dilute shareholders. Failure to obtain funding could force reductions or delays in programs.
- Other disclosed risks include competition, intellectual-property disputes and protection, product liability, healthcare regulation, and uncertainty in clinical-trial timing and results. The company reported that disclosure controls were effective at a reasonable-assurance level and no material change in internal control over financial reporting occurred during the quarter.
Most important facts for investors to verify
- JAKAFI prescription growth, net realized revenue, reimbursement coverage, patient access and the assumptions supporting the sell-through revenue model.
- Whether the anticipated $40.0 million Novartis milestone was received in Q2 2012, and the timing and terms of any further milestones or royalties.
- Cash burn and liquidity relative to the company’s stated 12-month capital-adequacy expectation, including the $19.0 million interest escrow and future debt service.
- Progress, costs and results for ruxolitinib and other pipeline trials, especially the Phase III polycythemia vera program and Lilly co-development obligations.
- Supply continuity and qualification of alternative sources for JAKAFI, as well as customer concentration and collection trends.
- How estimated product discounts and rebates, collaboration revenue recognition and convertible-note carrying values affect reported results.